Fixed-dose combinations in the management of hypertension: Defining the place of angiotensin receptor antagonists and hydrochlorothiazide

被引：42

作者：

Kjeldsen S.E. ^{[1
,2
]}

Os I. ^{[3
,4
]}

Høieggen A. ^{[4
]}

Beckey K. ^{[5
]}

Gleim G.W. ^{[5
]}

Oparil S. ^{[6
]}

机构：

[1] Department of Cardiology, Ullevaal University Hospital

[2] Division of Cardiovascular Medicine, University of Michigan, Ann Arbor, MI

[3] Institute of Pharmacotherapy, University of Oslo Medical School, Oslo

[4] Department of Nephrology, Ullevaal University Hospital

[5] Merck Research Labs., West Point, PA

[6] University of Alabama, Vascular Biology/Hypertension Prog., Birmingham, AL

来源：

American Journal of Cardiovascular Drugs | 2005年 / 5卷 / 1期

关键词：

Losartan; Amlodipine; Hydrochlorothiazide; Thiazide; Valsartan;

D O I：

10.2165/00129784-200505010-00003

中图分类号：

学科分类号：

摘要：

We discuss combination therapy with angiotensin receptor antagonists (angiotensin receptor blockers; ARBs) and thiazide diuretics in light of the independent actions of both types of agents, and the adverse effects of both agents independently and in the context of the physiologic synergy achieved in using these agents together. ARBs counteract many of the adverse events associated with the use of thiazide diuretics and have been shown to reduce the occurrence of new-onset diabetes mellitus. We also review outcome trials in patients with hypertension (such as LIFE [Losartan Intervention For Endpoint reduction in hypertension], VALUE [Valsartan Antihypertensive Long-term Use Evaluation], and SCOPE [Study on COgnition and Prognosis in the Elderly]), in which losartan, valsartan, and candesartan cilexetil were used in combination with hydrochlorothiazide. Fixed combination ARB/hydrochlorothiazide agents make sense as initial therapy for patients in whom BP is >20/10mm Hg above goal. © 2005 Adis Data Information BV. All rights reserved.

引用

页码：17 / 22

页数：5

共 33 条

[1]

Chobanian A.V., Bakris G.L., Black H.R., Et al., The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report, JAMA, 289, pp. 2560-2571, (2003)

[2]

Amer J., Hypertension in high-risk patients: Beware of the underuse of effective combination therapy (results of the PRATIK study), J. Hypertens., 20, pp. 779-784, (2002)

[3]

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT), JAMA, 288, pp. 2981-2997, (2002)

[4]

Dahlof B., Devereux R.B., Kjeldsen S.E., Et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol, Lancet, 359, pp. 995-1003, (2002)

[5]

European Society of Hypertension/European Society of Cardiology guidelines for the management of arterial hypertension: Guidelines Committee 2003, J. Hypertens., 6, pp. 1011-1053, (2003)

[6]

Mudge G.H., Diuretics and other agents employed in the mobilization of edema fluid, The Pharmacological Basis of Therapeutics, pp. 892-915, (1980)

[7]

Carter B.L., Ernst M.E., Cohen J.D., Hydrochlorothiazide versus chlorthalidone: Evidence supporting their interchangeability, Hypertension, 43, pp. 4-9, (2004)

[8]

Goth A., Diuretic drugs, Medical Pharmacology, pp. 426-444, (1978)

[9]

Weiner I.M., Mudge G.H., Diuretics and other agents employed in the mobilization of edema fluid, Goodman and Gilman's the Pharmacological Basis of Therapeutics, (1985)

[10]

Roberts C.J., Marshall A.J., Heaton S., Et al., Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone, BMJ, 1, pp. 224-226, (1979)

← 1 2 3 4 →